About: Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis
Creator	Li, Juan Liu, Dong Luo, Pan Liu, † Qiu, † Liu, Wen-Hua Liu, Xiu-Lan Xue, Hui-Ying Zheng, Jian-Ling
Source	Medline; PMC
abstract	Metformin was proposed to be a candidate for host-directed therapy for COVID-19. However, its efficacy remains to be validated. In this study, we compared the outcome of metformin users and nonusers in hospitalized COVID-19 patients with diabetes. Hospitalized diabetic patients with confirmed COVID-19 in the Tongji Hospital of Wuhan, China, from January 27, 2020 to March 24, 2020, were grouped into metformin and no-metformin groups according to the diabetic medications used. The demographics, characteristics, laboratory parameters, treatments, and clinical outcome in these patients were retrospectively assessed. A total of 283 patients (104 in the metformin and 179 in the no-metformin group) were included in this study. There were no significant differences between the two groups in gender, age, underlying diseases, clinical severity, and oxygen-support category at admission. The fasting blood glucose level of the metformin group was higher than that of the no-metformin group at admission and was under effective control in both groups after admission. Other laboratory parameters at admission and treatments after admission were not different between the two groups. The length of hospital stay did not differ between the two groups (21.0 days for metformin versus 19.5 days for no metformin, P = 0.74). However, in-hospital mortality was significantly lower in the metformin group (3/104 (2.9%) versus 22/179 (12.3%), P = 0.01). Antidiabetic treatment with metformin was associated with decreased mortality compared with diabetics not receiving metformin. This retrospective analysis suggests that metformin may offer benefits in patients with COVID-19 and that further study is indicated.
has issue date	2020-05-21(xsd:dateTime)
bibo:doi	10.4269/ajtmh.20-0375
bibo:pmid	32446312
has license	cc-by
sha1sum (hex)	19246ffe12612b47ade83e1a65461010797c588f
schema:url	https://doi.org/10.4269/ajtmh.20-0375
resource representing a document's title	Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis
has PubMed Central identifier	PMC7356425
has PubMed identifier	32446312
schema:publication	Am J Trop Med Hyg
resource representing a document's body	covid:19246ffe12612b47ade83e1a65461010797c588f#body_text
is schema:about of	named entity 'metformin' named entity 'Tongji' named entity 'therapy' named entity 'metformin' named entity 'Patients' named entity 'groups' named entity 'study' named entity 'control' named entity 'length' named entity 'age' named entity 'level' named entity 'patients' named entity 'COVID-19' named entity 'Metformin' named entity 'metformin' named entity 'metformin' named entity 'metformin' named entity 'diabetics' named entity 'diabetes' named entity 'Metformin' named entity 'COVID-19' named entity 'host-directed' named entity 'retrospectively' named entity 'mechanical ventilation' named entity 'oxygen saturation' named entity 'metformin' named entity 'microbiota' named entity 'pneumonia' named entity 'M2 macrophages' named entity 'clinical features' named entity 'acute respiratory distress syndrome' named entity 'COVID' named entity 'leukocytes' named entity 'glucose' named entity '0.01' named entity 'glucose production' named entity 'autophagy' named entity 'metformin' named entity 'platelet count' named entity 'immune response' named entity 'IgM' named entity 'metformin' named entity 'nephrosis' named entity 'COVID-19' named entity 'Statistical analysis' named entity 'host-directed' named entity 'National Health Commission of China' named entity 'respiratory failure' named entity 'cytokine storms' named entity 'ritonavir' named entity 'clinical symptoms' named entity 'lymphocytes' named entity 'infection' named entity 'body contact' named entity 'metformin' named entity 'chemokines' named entity 'protein kinase' named entity 'kidney function' named entity 'COVID' named entity 'COVID' named entity 'metformin' named entity 'host-directed' named entity 'metformin' named entity 'Tongji Medical College' named entity 'C-reactive protein' named entity 'inflammation' named entity 'fibrosis' named entity 'COVID-19' named entity 'COVID' named entity 'metformin' named entity 'reduce inflammation' named entity 'hypertension' named entity 'diabetic'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software